Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

10x Genomics (TXG) Other financing activities (2019 - 2023)

Historic Other financing activities for 10x Genomics (TXG) over the last 5 years, with Q1 2023 value amounting to $5.8 million.

  • 10x Genomics' Other financing activities rose 748.75% to $5.8 million in Q1 2023 from the same period last year, while for Dec 2023 it was $5.8 million, marking a year-over-year increase of 748.75%. This contributed to the annual value of $5.8 million for FY2023, which is 748.75% up from last year.
  • Latest data reveals that 10x Genomics reported Other financing activities of $5.8 million as of Q1 2023, which was up 748.75% from $5.4 million recorded in Q1 2022.
  • Over the past 5 years, 10x Genomics' Other financing activities peaked at $5.8 million during Q1 2020, and registered a low of -$1.9 million during Q3 2019.
  • Over the past 5 years, 10x Genomics' median Other financing activities value was $5.0 million (recorded in 2021), while the average stood at $3.2 million.
  • In the last 5 years, 10x Genomics' Other financing activities plummeted by 1399.25% in 2021 and then soared by 757.76% in 2022.
  • 10x Genomics' Other financing activities (Quarter) stood at -$1.9 million in 2019, then surged by 100.1% to $2000.0 in 2020, then skyrocketed by 251300.0% to $5.0 million in 2021, then increased by 7.58% to $5.4 million in 2022, then rose by 7.49% to $5.8 million in 2023.
  • Its Other financing activities was $5.8 million in Q1 2023, compared to $5.4 million in Q1 2022 and $5.0 million in Q1 2021.